Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523744 | 0.92 | CHRNB2 (0.64) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL29832812 | 0.92 | CHRNB2 (0.64) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL9561277 | 0.91 | CHRNB2 (0.59) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL31087898 | 0.90 | CHRNB2 (0.62) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL5518334 | 0.90 | CHRNB2 (0.62) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL15498199 | 0.90 | CHRNB2 (0.73) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL31087900 | 0.89 | CHRNB2 (0.61) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL8955653 | 0.89 | CHRNB2 (0.61) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL31087905 | 0.89 | CHRNB2 (0.61) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL16943480 | 0.87 | CHRNB2 (0.66) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109880876-B | Method for preparing (R) -m-nitrophenyl glycol by using bean epoxide hydrolase | 江南大学 | 2021-03-30 | — | — | CN | claimed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20240059733-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-22 | — | — | US | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3985001-A1 | PHARMACEUTICAL COMPOSITION USEFUL IN INHIBITING IDH1 | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3447052-B1 | METHODS OF PREPARING NEW IDH1 INHIBITORS | LES LABORATOIRES SERVIER SAS (FR) | 2021-10-20 | — | — | EP | disclosed |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| US-5273993-A | Antiarthritic agents; osteoporosis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5194446-A | Antiarthritic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-16 | — | — | US | disclosed |
| US-5192785-A | Sulfamates as antiglaucoma agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-09 | — | — | US | disclosed |
| EP-0355492-B1 | REACTIVE DYES | BAYER AG (DE) | 1992-12-09 | — | — | EP | disclosed |
| US-5138054-A | Colorfastness, photostability; red dye | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| US-5025031-A | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants | A. H. ROBINS CO., INC. (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0355492-A1 | Reactive dyes | BAYER AG (DE) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021515-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | CHRNB2 3371/4885CHRNA4 4371/4885ALDH1A1 413/4885 |
| US-20240059733-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | CHRNB2 3371/4885CHRNA4 4371/4885ALDH1A1 413/4885 |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | CHRNB2 3371/4885CHRNA4 4371/4885ALDH1A1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.